

and Public Law 113–56 (PEPFAR Stewardship and Oversight Act of 2013).

Additionally, these programs are authorized under Section 307 of the Public Health Service Act, as amended [42 U.S.C. 242l], Section 301 (a) [42 U.S.C. 241 (a)] of the Public Health Service Act, as amended.

Period of performance: September 30, 2026, through September 29, 2031.

Jamie Legier,

Chief Grants Management Officer, Centers for Disease Control and Prevention.

[FR Doc. 2026–16731 Filed 8–14–26; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Notice of Award of a Sole Source Cooperative Agreement To Fund University Teaching Hospital in Zambia

AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice.

SUMMARY: The Centers for Disease Control and Prevention (CDC), located within the Department of Health and Human Services (HHS), announces the award of approximately \$30,000,000, for Federal Fiscal Year 2026 funding to Zambia's University Teaching Hospital (UTH), subject to availability of funds. Funding amounts for years 2–5 will be set at continuation. The award is expected to improve HIV and TB clinical and laboratory service delivery at referral level hospitals and provincial-level referral facilities through the national government referral facility, UTH.

DATES: The period for this award will be September 30, 2026, through September 29, 2031.

FOR FURTHER INFORMATION CONTACT: Cristel Bender, Global Health Center, Centers for Disease Control and Prevention, 1600 Clifton Rd. NE, Atlanta, GA 30329, Email: DGHTNOFOs@cdc.gov.

SUPPLEMENTARY INFORMATION: The sole source award is expected to improve HIV and TB clinical and laboratory service delivery at referral level hospitals and provincial-level referral facilities through the national government referral facility, UTH.

UTH is the only entity that can carry out this work, as it is the country's national reference hospital, with a directive to provide inpatient and

outpatient services for complicated cases, including advanced HIV disease cases.

Summary of the Award

Recipient: University Teaching Hospital.

Purpose of the award: The purpose of this award is to support sustainable HIV and TB service implementation through UTH.

Authority: This program is authorized under Public Law 108–25 (the United States Leadership Against HIV AIDS, Tuberculosis and Malaria Act of 2003) [22 U.S.C. 7601, *et seq.*] and Public Law 110–293 (the Tom Lantos and Henry J. Hyde United States Global Leadership Against HIV/AIDS, Tuberculosis, and Malaria Reauthorization Act of 2008), Public Law 113–56 (PEPFAR Stewardship and Oversight Act of 2013), and Public Health Service Act (42 U.S.C. 242l).

Period of performance: September 30, 2026, through September 29, 2031.

Jamie Legier,

Chief Grants Management Officer, Centers for Disease Control and Prevention.

[FR Doc. 2026–16732 Filed 8–14–26; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

Withdrawal of the Announcement of the Intent To Award a Single-Source Cooperative Agreement to Burke Law Group, PLLC in Houston, Texas

AGENCY: Office of Refugee Resettlement (ORR), Administration for Children and Families (ACF), Department of Health and Human Services (HHS).

ACTION: Notice of intent to award a single-source cooperative agreement; withdrawal.

SUMMARY: The Administration for Children and Families (ACF), Office of Refugee Resettlement (ORR), is withdrawing the, 'Announcement of the Intent to Award a Single-Source Cooperative Agreement to Burke Law Group, PLLC in Houston, Texas' published in the **Federal Register** on August 6, 2026, at 91 FR 50848 (FR Doc. 2026–16081).

FOR FURTHER INFORMATION CONTACT: Reina Byrd, Assistant Deputy Director, Unaccompanied Alien Children Bureau, 330 C St SW, Washington, DC 20201. Telephone: (202) 256–9497; Email: Reina.Byrd@acf.hhs.gov.

SUPPLEMENTARY INFORMATION:

Withdrawal Notice

In the **Federal Register** of August 6, 2026, at 91 FR 50848 (FR Doc. 2026–16081), page 50848, ORR published a notice announcing its intent to award a single-source cooperative agreement of up to \$150,000,000 to Burke Law Group, PLLC, in Houston, Texas, to provide legal services for eligible unaccompanied alien children (UAC) in ORR care.

Burke Law Group subsequently notified ORR of its decision not to apply for the proposed cooperative agreement and withdrew from consideration on August 11, 2026. Therefore, ORR will not make the award to Burke Law Group announced in the notice published on August 6, 2026. This withdrawal does not affect ORR's continued efforts to ensure access to legal services for eligible UACs in ORR care.

Statutory Authority: Section 462 of the Homeland Security Act of 2002, 6 U.S.C. 279; William Wilberforce Trafficking Victims Protection Reauthorization Act of 2008, 8 U.S.C. 1232(c)(4) and (c)(5).

Dawnisha Helland,

Assistant Principal Deputy Director, Unaccompanied Alien Children Bureau, Office of Refugee Resettlement.

[FR Doc. 2026–16741 Filed 8–13–26; 11:15 am]

BILLING CODE 4184–45–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2024–D–5376]

Type VII Veterinary Master File for Research and Development and Risk Reviews; Guidance for Industry; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of availability.

SUMMARY: The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a final guidance for industry (GFI) #260 entitled "Type VII Veterinary Master File for Research and Development and Risk Reviews." This guidance describes FDA's current thinking regarding the use of Type VII Veterinary Master Files (Type VII VMFs). Type VII VMFs are appropriate for research and development of animal cells, tissues, and cell- and tissue-based products (ACTPs), gene therapies, and heritable intentional genomic alterations (IGAs) in animals.

DATES: The announcement of the guidance is published in the **Federal Register** on August 17, 2026.

ADDRESSES: You may submit comments on any guidance at any time as follows:

Electronic Submissions

Submit electronic comments in the following way:

- **Federal eRulemaking Portal:** <https://www.regulations.gov>. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to <https://www.regulations.gov> will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on <https://www.regulations.gov>.

- If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see "Written/Paper Submissions" and "Instructions").

Written/Paper Submissions

Submit written/paper submissions as follows:

- Mail/Hand Delivery/Courier (for written/paper submissions): Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

- For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in "Instructions."

Instructions: All submissions received must include the Docket No. FDA-2024-D-5376 for "Type VII Veterinary Master File for Research and Development and Risk Reviews." Received comments will be placed in the docket and, except for those submitted as "Confidential Submissions," publicly viewable at <https://www.regulations.gov> or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday, 240-402-7500.

- Confidential Submissions—To submit a comment with confidential information that you do not wish to be

made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states "THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION." The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on <https://www.regulations.gov>. Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as "confidential." Any information marked as "confidential" will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA's posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: <https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf>.

Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to <https://www.regulations.gov> and insert the docket number, found in brackets in the heading of this document, into the "Search" box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240-402-7500.

You may submit comments on any guidance at any time (see 21 CFR 10.115(g)(5)).

Submit written requests for single copies of the guidance to the Policy and Regulations Staff, Center for Veterinary Medicine, Food and Drug Administration, 5001 Campus Dr., College Park, MD 20740. Send one self-addressed adhesive label to assist that office in processing your requests. See the **SUPPLEMENTARY INFORMATION** section for electronic access to the guidance document.

FOR FURTHER INFORMATION CONTACT:

Lynne Boxer, Center for Veterinary Medicine, Food and Drug Administration, 5001 Campus Dr., College Park, MD 20740, 240-402-0611, lynne.boxer@fda.hhs.gov.

SUPPLEMENTARY INFORMATION:

I. Background

In the **Federal Register** of January 7, 2025 (90 FR 1143), FDA published the notice of availability for a draft guidance entitled "Type VII Veterinary Master File for Research and Development and Risk Reviews" giving interested persons until March 10, 2025, to comment on the draft guidance. FDA received one comment on the draft guidance asking for additional time to review and comment on the draft guidance. In the **Federal Register** of April 9, 2025 (90 FR 15248), FDA extended the comment period of the draft guidance until June 9, 2025. FDA received no additional comments on the draft guidance and FDA has, therefore, made no substantive changes to the draft guidance. The guidance announced in this notice finalizes the draft guidance dated January 2025.

This level 1 guidance is being issued consistent with FDA's good guidance practices regulation (21 CFR 10.115). The guidance represents the current thinking of FDA on Type VII Veterinary Master File for Research and Development and Risk Reviews. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations.

II. Paperwork Reduction Act of 1995

While this guidance contains no collection of information, it does refer to previously approved FDA collections of information. The previously approved collections of information are subject to review by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C. 3501-3521). The collections of information in 21 CFR part 514 have been approved under OMB control number 0910-0032.

III. Electronic Access

Persons with access to the internet may obtain the guidance at <https://www.fda.gov/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndustry/default.htm>, <https://www.fda.gov/regulatory-information/search-fda-guidance-documents>, or <https://www.regulations.gov>.

Grace R. Graham,

Deputy Commissioner for Policy, Legislation, and International Affairs.

[FR Doc. 2026-16711 Filed 8-14-26; 8:45 am]

BILLING CODE 4164-01-P